Role of antispasmodics in the treatment of irritable bowel syndrome

World Journal of Gastroenterology

Volumn 20, Issue 20, 2014, Pages 6031-6043

  Annaházi, Anita ^a   Róka, Richárd ^a   Rosztóczy, András ^a   Wittmann, Tibor ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

Author keywords

Calcium channel blockers; Irritable bowel syndrome; Motility; Spasmolytics; Treatment

Indexed keywords

ACETYLCHOLINE; ALVERINE CITRATE; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; CALCIUM CHANNEL T TYPE; CHOLECYSTOKININ; DIGESTIVE TRACT AGENT; DIZOCILPINE; GALLOPAMIL; MEBEVERINE; METHYLCELLULOSE; MUSCARINIC M1 RECEPTOR; MUSCARINIC M2 RECEPTOR; MUSCARINIC M4 RECEPTOR; MUSCARINIC M5 RECEPTOR; MUSCARINIC RECEPTOR; MUSCLE RELAXANT AGENT; NITRENDIPINE; NITRIC OXIDE; OTILONIUM BROMIDE; PAPAVERINE; PHLOROGLUCINOL; PINAVERIUM BROMIDE; PLACEBO; PROSTAGLANDIN; SEROTONIN 1A ANTAGONIST; SIMETHICONE; SPASMOLYTIC AGENT; TRIMETHYLPHLOROGLUCINOL; UNCLASSIFIED DRUG; UNINDEXED DRUG; VOLTAGE GATED CALCIUM CHANNEL; CALCIUM CHANNEL; CHOLINERGIC RECEPTOR BLOCKING AGENT; MORPHOLINE DERIVATIVE; OCTYLONIUM; PHENETHYLAMINE DERIVATIVE; PINAVERIUM; QUATERNARY AMMONIUM DERIVATIVE;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ANXIETY; ARTICLE; BLOOD PRESSURE; COGNITIVE THERAPY; COLON MOTILITY; DEPOLARIZATION; DEPRESSION; DIETARY FIBER; DRUG EFFICACY; HUMAN; HYPERSENSITIVITY; INTESTINE ABSORPTION; IRRITABLE COLON; LYMPHOCYTE COUNT; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; SPHINCTER; STRESS; SYSTEMATIC REVIEW (TOPIC); VISUAL ANALOG SCALE; ANIMAL; CHEMISTRY; DISEASE MODEL; IRRITABLE BOWEL SYNDROME; METABOLISM; TREATMENT OUTCOME;

ABDOMINAL PAIN; ANIMALS; CALCIUM; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS; DISEASE MODELS, ANIMAL; HUMANS; IRRITABLE BOWEL SYNDROME; MORPHOLINES; PARASYMPATHOLYTICS; PHENETHYLAMINES; QUATERNARY AMMONIUM COMPOUNDS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84901489013     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i20.6031     Document Type: Article

References (110)

1. Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol 2012; 10: 712-721.e4. [PMID: 22426087 DOI: 10.1016/j.cgh.2012.02.029]
2. Agarwal N, Spiegel BM. The effect of irritable bowel syndrome on health-related quality of life and health care expenditures. Gastroenterol Clin North Am 2011; 40: 11-19. [PMID: 21333898 DOI: 10.1016/j.gtc.2010.12.013]
3. Longstreth GF, Wilson A, Knight K, Wong J, Chiou CF, Barghout V, Frech F, Ofman JJ. Irritable bowel syndrome, health care use, and costs: a U.S. managed care perspective. Am J Gastroenterol 2003; 98: 600-607. [PMID: 12650794]
4. Quigley EM, Abdel-Hamid H, Barbara G, Bhatia SJ, Boeckxstaens G, De Giorgio R, Delvaux M, Drossman DA, Foxx-Orenstein AE, Guarner F, Gwee KA, Harris LA, Hungin AP, Hunt RH, Kellow JE, Khalif IL, Kruis W, Lindberg G, Olano C, Moraes-Filho JP, Schiller LR, Schmulson M, Simrén M, Tzeuton C. A global perspective on irritable bowel syndrome: a consensus statement of the World Gastroenterology Organisation Summit Task Force on irritable bowel syndrome. J Clin Gastroenterol 2012; 46: 356-366. [PMID: 22499071 DOI: 10.1097/MCG.0b013e318247157c]
5. Casiday RE, Hungin AP, Cornford CS, de Wit NJ, Blell MT. GPs' explanatory models for irritable bowel syndrome: a mismatch with patient models? Fam Pract 2009; 26: 34-39. [PMID: 19011171 DOI: 10.1093/fampra/cmn088]
6. Agréus L, Svärdsudd K, Talley NJ, Jones MP, Tibblin G. Natural history of gastroesophageal reflux disease and functional abdominal disorders: a population-based study. Am J Gastroenterol 2001; 96: 2905-2914. [PMID: 11693325 DOI: 10.1111/j.1572-0241.2001.04680.x]
7. Evangelista S. Benefits from long-term treatment in irritable bowel syndrome. Gastroenterol Res Pract 2012; 2012: 936-960. [PMID: 22272195 DOI: 10.1155/2012/936960]
8. Poynard T, Regimbeau C, Benhamou Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2001; 15: 355-361. [PMID: 11207510]
9. Lièvre M. Alosetron for irritable bowel syndrome. BMJ 2002; 325: 555-556. [PMID: 12228116]
10. Manning AP, Thompson WG, Heaton KW, Morris AF. Towards positive diagnosis of the irritable bowel. Br Med J 1978; 2: 653-654. [PMID: 698649]
11. Drossman DA, Grant Thomson W, Talley NJ, Funch-Jensen P, Janssen J, Whitehead WE. Identification of sub-groups of functional gastrointestinal disorders. Gastroenterol Int 1990; 3: 159-172
12. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006; 130: 1480-1491. [PMID: 16678561 DOI: 10.1053/ j.gastro.2005.11.061]
13. Guilera M, Balboa A, Mearin F. Bowel habit subtypes and temporal patterns in irritable bowel syndrome: systematic review. Am J Gastroenterol 2005; 100: 1174-1184. [PMID: 15842596 DOI: 10.1111/j.1572-0241.2005.40674.x]
14. Spiller RC. Role of infection in irritable bowel syndrome. J Gastroenterol 2007; 42 Suppl 17: 41-47. [PMID: 17238025 DOI: 10.1007/s00535-006-1925-8]
15. McKendrick MW, Read NW. Irritable bowel syndrome-post salmonella infection. J Infect 1994; 29: 1-3. [PMID: 7963621]
16. Neal KR, Hebden J, Spiller R. Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients. BMJ 1997; 314: 779-782. [PMID: 9080994]
17. Mayer EA, Naliboff BD, Craig AD. Neuroimaging of the brain-gut axis: from basic understanding to treatment of functional GI disorders. Gastroenterology 2006; 131: 1925-1942. [PMID: 17188960]
18. Fichna J, Storr MA. Brain-Gut Interactions in IBS. Front Pharmacol 2012; 3: 127. [PMID: 22783191 DOI: 10.3389/ fphar.2012.00127]
19. Whitehead WE. Psychosocial aspects of functional gastrointestinal disorders. Gastroenterol Clin North Am 1996; 25: 21-34. [PMID: 8682574]
20. Drossman DA, Ringel Y, Vogt BA, Leserman J, Lin W, Smith JK, Whitehead W. Alterations of brain activity associated with resolution of emotional distress and pain in a case of severe irritable bowel syndrome. Gastroenterology 2003; 124: 754-761. [PMID: 12612913 DOI: 10.1053/gast.2003.50103]
21. Yuan YZ, Tao RJ, Xu B, Sun J, Chen KM, Miao F, Zhang ZW, Xu JY. Functional brain imaging in irritable bowel syndrome with rectal balloon-distention by using fMRI. World J Gastroenterol 2003; 9: 1356-1360. [PMID: 12800256]
22. Bouin M, Plourde V, Boivin M, Riberdy M, Lupien F, Laganière M, Verrier P, Poitras P. Rectal distention testing in patients with irritable bowel syndrome: sensitivity, specificity, and predictive values of pain sensory thresholds. Gastroenterology 2002; 122: 1771-1777. [PMID: 12055583]
23. Gecse K, Róka R, Ferrier L, Leveque M, Eutamene H, Cartier C, Ait-Belgnaoui A, Rosztóczy A, Izbéki F, Fioramonti J, Wittmann T, Bueno L. Increased faecal serine protease activity in diarrhoeic IBS patients: a colonic lumenal factor impairing colonic permeability and sensitivity. Gut 2008; 57: 591-599. [PMID: 18194983 DOI: 10.1136/gut.2007.140210]
24. Gecse K, Róka R, Séra T, Rosztóczy A, Annaházi A, Izbéki F, Nagy F, Molnár T, Szepes Z, Pávics L, Bueno L, Wittmann T. Leaky gut in patients with diarrhea-predominant irritable bowel syndrome and inactive ulcerative colitis. Digestion 2012; 85: 40-46. [PMID: 22179430 DOI: 10.1159/000333083]
25. Annaházi A, Ferrier L, Bézirard V, Lévêque M, Eutamène H, Ait-Belgnaoui A, Coëffier M, Ducrotté P, Róka R, Inczefi O, Gecse K, Rosztóczy A, Molnár T, Ringel-Kulka T, Ringel Y, Piche T, Theodorou V, Wittmann T, Bueno L. Luminal cysteine-proteases degrade colonic tight junction structure and are responsible for abdominal pain in constipation-predominant IBS. Am J Gastroenterol 2013; 108: 1322-1331. [PMID: 23711626 DOI: 10.1038/ajg.2013.152]
26. Ahn JY, Lee KH, Choi CH, Kim JW, Lee HW, Kim JW, Kim MK, Kwon GY, Han S, Kim SE, Kim SM, Chang SK. Colonic mucosal immune activity in irritable bowel syndrome: comparison with healthy controls and patients with ulcerative colitis. Dig Dis Sci 2014; 59: 1001-1011. [PMID: 24282051 DOI: 10.1007/s10620-013-2930-4]
27. Barbara G, Stanghellini V, De Giorgio R, Cremon C, Cottrell GS, Santini D, Pasquinelli G, Morselli-Labate AM, Grady EF, Bunnett NW, Collins SM, Corinaldesi R. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004; 126: 693-702. [PMID: 14988823]
28. Dunlop SP, Jenkins D, Neal KR, Spiller RC. Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology 2003; 125: 1651-1659. [PMID: 14724817]
29. Grider JR, Foxx-Orenstein AE, Jin JG. 5-Hydroxytryptamine4 receptor agonists initiate the peristaltic reflex in human, rat, and guinea pig intestine. Gastroenterology 1998; 115: 370-380. [PMID: 9679042]
30. Tam FS, Hillier K, Bunce KT. Characterization of the 5-hydroxytryptamine receptor type involved in inhibition of spontaneous activity of human isolated colonic circular muscle. Br J Pharmacol 1994; 113: 143-150. [PMID: 7812604]
31. Kanazawa M, Palsson OS, Thiwan SI, Turner MJ, van Tilburg MA, Gangarosa LM, Chitkara DK, Fukudo S, Drossman DA, Whitehead WE. Contributions of pain sensitivity and colonic motility to IBS symptom severity and predominant bowel habits. Am J Gastroenterol 2008; 103: 2550-2561. [PMID: 18684175 DOI: 10.1111/j.1572-0241.2008.02066.x]
32. Lind CD. Motility disorders in the irritable bowel syndrome. Gastroenterol Clin North Am 1991; 20: 279-295. [PMID: 2066153]
33. Wittmann T, Crenner F, Angel F, Hanusz L, Ringwald C, Grenier JF. Long-duration stress. Immediate and late effects on small and large bowel motility in rat. Dig Dis Sci 1990; 35: 495-500. [PMID: 2318096]
34. Wittmann T, Vaxman F, Crenner F, Angel F, Grenier JF. Colonic electromyographic changes in irritable bowel syndrome (IBS). In: Varró V, de Chatel R, editors. 22 nd Congress of the International Society of Internal Medicine: ed. Monduzzi Editore, 1994: 125-131
35. Wittmann T, Vaxman F, Crenner F, Grenier JF. Alterations specifiques de la motricité colique dans la colopathie fonctionelle et constipation chronique. Gastroenterol Clin Biol 1991; 15: 135A
36. Fukudo S, Kanazawa M, Kano M, Sagami Y, Endo Y, Utsumi A, Nomura T, Hongo M. Exaggerated motility of the descending colon with repetitive distention of the sigmoid colon in patients with irritable bowel syndrome. J Gastroenterol 2002; 37 Suppl 14: 145-150. [PMID: 12572883]
37. Kellow JE, Phillips SF. Altered small bowel motility in irritable bowel syndrome is correlated with symptoms. Gastroenterology 1987; 92: 1885-1893. [PMID: 3569764]
38. Clavé P. Treatment of IBS-D with 5-HT3 receptor antagonists vs spasmolytic agents: similar therapeutical effects from heterogeneous pharmacological targets. Neurogastroenterol Motil 2011; 23: 1051-1055. [PMID: 22093116 DOI: 10.1111/j.1365-2982.2011.01808.x]
39. Catterall WA, Perez-Reyes E, Snutch TP, Striessnig J. International Union of Pharmacology. XLVIII. Nomenclature and structure-function relationships of voltage-gated calcium channels. Pharmacol Rev 2005; 57: 411-425. [PMID: 16382099 DOI: 10.1124/pr.57.4.5]
40. Kochegarov AA. Pharmacological modulators of voltagegated calcium channels and their therapeutical application. Cell Calcium 2003; 33: 145-162. [PMID: 12600802]
41. Nowycky MC, Fox AP, Tsien RW. Three types of neuronal calcium channel with different calcium agonist sensitivity. Nature 1985; 316: 440-443. [PMID: 2410796]
42. Prior A, Harris SR, Whorwell PJ. Reduction of colonic motility by intravenous nicardipine in irritable bowel syndrome. Gut 1987; 28: 1609-1612. [PMID: 3428688]
43. Abysique A, Lucchini S, Orsoni P, Mei N, Bouvier M. Effects of alverine citrate on cat intestinal mechanoreceptor responses to chemical and mechanical stimuli. Aliment Pharmacol Ther 1999; 13: 561-566. [PMID: 10215743]
44. Coelho AM, Jacob L, Fioramonti J, Bueno L. Rectal antinociceptive properties of alverine citrate are linked to antagonism at the 5-HT1A receptor subtype. J Pharm Pharmacol 2001; 53: 1419-1426. [PMID: 11697552]
45. Bueno L, Beaufrand C, Theodorou V, Andro-Delestrain MC. Influence of simethicone and alverine on stress-induced alterations of colonic permeability and sensitivity in rats: beneficial effect of their association. J Pharm Pharmacol 2013; 65: 567-573. [PMID: 23488786 DOI: 10.1111/jphp.12021]
46. Mitchell SA, Mee AS, Smith GD, Palmer KR, Chapman RW. Alverine citrate fails to relieve the symptoms of irritable bowel syndrome: results of a double-blind, randomized, placebo-controlled trial. Aliment Pharmacol Ther 2002; 16: 1187-1195. [PMID: 12030962]
47. Altintaş E, Uçbilek E, Sezgin O, Sayici Y. Alverine citrate plus simethicone reduces cecal intubation time in colonoscopy - a randomized study. Turk J Gastroenterol 2008; 19: 174-179. [PMID: 19115153]
48. Wittmann T, Paradowski L, Ducrotté P, Bueno L, Andro Delestrain MC. Clinical trial: the efficacy of alverine citrate/ simeticone combination on abdominal pain/discomfort in irritable bowel syndrome--a randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther 2010; 31: 615-624. [PMID: 20003095 DOI: 10.1111/j.1365-2036.2009.04216.x]
49. Den Hertog A, Van den Akker J. Modification of alpha 1-receptor-operated channels by mebeverine in smooth muscle cells of guinea-pig taenia caeci. Eur J Pharmacol 1987; 138: 367-374. [PMID: 2442008]
50. Greenslade FC, Scott CK, Newquist KL, Krider KM, Chasin M. Heterogeneity of biochemical actions among vasodilators. J Pharm Sci 1982; 71: 94-100. [PMID: 6276530]
51. Lindner A, Selzer H, Claassen V, Gans P, Offringa OR, Zwagemakers JM. Pharmacological properties of mebeverine, a smooth-muscle relaxant. Arch Int Pharmacodyn Ther 1963; 145: 378-395. [PMID: 14067562]
52. Connell AM. Physiological and clinical assessment of the effect of the musculotropic agent mebeverine on the human colon. Br Med J 1965; 2: 848-851. [PMID: 5318612]
53. Evans PR, Bak YT, Kellow JE. Mebeverine alters small bowel motility in irritable bowel syndrome. Aliment Pharmacol Ther 1996; 10: 787-793. [PMID: 8899088]
54. Van Outryve M, Mayeur S, Meeus MA, Rosillon D, Hendrickx B, Ceuppens M. A double-blind crossover comparison study of the safety and efficacy of mebeverine with mebeverine sustained release in the treatment of irritable bowel syndrome. J Clin Pharm Ther 1995; 20: 277-282. [PMID: 8576295]
55. Lu CL, Chen CY, Chang FY, Chang SS, Kang LJ, Lu RH, Lee SD. Effect of a calcium channel blocker and antispasmodic in diarrhoea-predominant irritable bowel syndrome. J Gastroenterol Hepatol 2000; 15: 925-930. [PMID: 11022835]
56. Lee KJ, Kim NY, Kwon JK, Huh KC, Lee OY, Lee JS, Choi SC, Sohn CI, Myung SJ, Park HJ, Choi MK, Bak YT, Rhee PL. Efficacy of ramosetron in the treatment of male patients with irritable bowel syndrome with diarrhea: a multicenter, randomized clinical trial, compared with mebeverine. Neurogastroenterol Motil 2011; 23: 1098-1104. [PMID: 21920001 DOI: 10.1111/j.1365-2982.2011.01771.x]
57. Darvish-Damavandi M, Nikfar S, Abdollahi M. A systematic review of efficacy and tolerability of mebeverine in irritable bowel syndrome. World J Gastroenterol 2010; 16: 547-553. [PMID: 20128021]
58. Kruis W, Weinzierl M, Schüssler P, Holl J. Comparison of the therapeutic effect of wheat bran, mebeverine and placebo in patients with the irritable bowel syndrome. Digestion 1986; 34: 196-201. [PMID: 3019810]
59. Enck P, Klosterhalfen S, Kruis W. [Determination of placebo effect in irritable bowel syndrome]. Dtsch Med Wochenschr 2005; 130: 1934-1937. [PMID: 16123895 DOI: 10.1055/ s-2005-872605]
60. Everitt HA, Moss-Morris RE, Sibelli A, Tapp L, Coleman NS, Yardley L, Smith PW, Little PS. Management of irritable bowel syndrome in primary care: feasibility randomised controlled trial of mebeverine, methylcellulose, placebo and a patient self-management cognitive behavioural therapy website. (MIBS trial). BMC Gastroenterol 2010; 10: 136. [PMID: 21087463 DOI: 10.1186/1471-230X-10-136]
61. Everitt H, Moss-Morris R, Sibelli A, Tapp L, Coleman N, Yardley L, Smith P, Little P. Management of irritable bowel syndrome in primary care: the results of an exploratory randomised controlled trial of mebeverine, methylcellulose, placebo and a self-management website. BMC Gastroenterol 2013; 13: 68. [PMID: 23602047 DOI: 10.1186/1471-230X-13-68]
62. Kennedy T, Jones R, Darnley S, Seed P, Wessely S, Chalder T. Cognitive behaviour therapy in addition to antispasmodic treatment for irritable bowel syndrome in primary care: randomised controlled trial. BMJ 2005; 331: 435. [PMID: 16093252 DOI: 10.1136/bmj.38545.505764.06]
63. Reme SE, Stahl D, Kennedy T, Jones R, Darnley S, Chalder T. Mediators of change in cognitive behaviour therapy and mebeverine for irritable bowel syndrome. Psychol Med 2011; 41: 2669-2679. [PMID: 21477419 DOI: 10.1017/S0033291711000328]
64. Evangelista S. Quaternary ammonium derivatives as spasmolytics for irritable bowel syndrome. Curr Pharm Des 2004; 10: 3561-3568. [PMID: 15579053]
65. Evangelista S, Cochet P, Bromet N, Criscuoli M, Maggi CA. A distribution study with (14)C-otilonium bromide in the rat: evidence for selective tropism for large intestine after oral administration. Drug Metab Dispos 2000; 28: 643-647. [PMID: 10820135]
66. Evangelista S, Giachetti A, Chapelain B, Neliat G, Maggi CA. Receptor binding profile of Otilonium bromide. Pharmacol Res 1998; 38: 111-117. [PMID: 9721598]
67. Lindqvist S, Hernon J, Sharp P, Johns N, Addison S, Watson M, Tighe R, Greer S, Mackay J, Rhodes M, Lewis M, Stebbings W, Speakman C, Evangelista S, Johnson I, Williams M. The colon-selective spasmolytic otilonium bromide inhibits muscarinic M(3) receptor-coupled calcium signals in isolated human colonic crypts. Br J Pharmacol 2002; 137: 1134-1142. [PMID: 12429587 DOI: 10.1038/sj.bjp.0704942]
68. Czimmer J, Süto G, Király A, Mózsik G. Otilonium bromide enhances sensory thresholds of volume and pressure in patients with irritable bowel syndrome. J Physiol Paris 2001; 95: 153-156. [PMID: 11595430]
69. Baldi F, Longanesi A, Blasi A, Monello S, Cestari R, Missale G, Corazziari E, Badiali G, Pescatori M, Anastasio G. Clinical and functional evaluation of the efficacy of otilonium bromide: a multicenter study in Italy. Ital J Gastroenterol 1991; 23: 60-63. [PMID: 1756285]
70. Battaglia G, Morselli-Labate AM, Camarri E, Francavilla A, De Marco F, Mastropaolo G, Naccarato R. Otilonium bromide in irritable bowel syndrome: a double-blind, placebocontrolled, 15-week study. Aliment Pharmacol Ther 1998; 12: 1003-1010. [PMID: 9798806]
71. Glende M, Morselli-Labate AM, Battaglia G, Evangelista S. Extended analysis of a double-blind, placebo-controlled, 15-week study with otilonium bromide in irritable bowel syndrome. Eur J Gastroenterol Hepatol 2002; 14: 1331-1338. [PMID: 12468954]
72. Clavé P, Acalovschi M, Triantafillidis JK, Uspensky YP, Kalayci C, Shee V, Tack J. Randomised clinical trial: otilonium bromide improves frequency of abdominal pain, severity of distention and time to relapse in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2011; 34: 432-442. [PMID: 21679214 DOI: 10.1111/j.1365-2036.2011.04730.x]
73. Boeckxstaens G, Corazziari ES, Mearin F, Tack J. IBS and the role of otilonium bromide. Int J Colorectal Dis 2013; 28: 295-304. [PMID: 23178991 DOI: 10.1007/s00384-012-1598-0]
74. Ford AC, Talley NJ, Spiegel BM, Foxx-Orenstein AE, Schiller L, Quigley EM, Moayyedi P. Effect of fibre, antispasmodics, and peppermint oil in the treatment of irritable bowel syndrome: systematic review and meta-analysis. BMJ 2008; 337: a2313. [PMID: 19008265 DOI: 10.1136/bmj.a2313]
75. Chang FY, Lu CL, Luo JC, Chen TS, Chen MJ, Chang HJ. The evaluation of otilonium bromide treatment in asian patients with irritable bowel syndrome. J Neurogastroenterol Motil 2011; 17: 402-410. [PMID: 22148110 DOI: 10.5056/ jnm.2011.17.4.402]
76. Christen MMO, Tassignon JP. Pinaverium bromide: A calcium channel blocker acting selectively on the gastrointestinal tract. Drug Dev Res 1989; 18: 101-112 [DOI: 10.1002/ ddr.430180202]
77. Malysz J, Farraway LA, Christen MO, Huizinga JD. Pinaverium acts as L-type calcium channel blocker on smooth muscle of colon. Can J Physiol Pharmacol 1997; 75: 969-975. [PMID: 9360010]
78. Baumgartner A, Drack E, Halter F, Scheurer U. Effects of pinaverium bromide and verapamil on the motility of the rat isolated colon. Br J Pharmacol 1985; 86: 89-94. [PMID: 4052731]
79. Boyer JC, Magous R, Christen MO, Balmes JL, Bali JP. Contraction of human colonic circular smooth muscle cells is inhibited by the calcium channel blocker pinaverium bromide. Cell Calcium 2001; 29: 429-438. [PMID: 11352508 DOI: 10.1054/ceca.2001.0205]
80. Dai Y, Liu JX, Li JX, Xu YF. Effect of pinaverium bromide on stress-induced colonic smooth muscle contractility disorder in rats. World J Gastroenterol 2003; 9: 557-561. [PMID: 12632518]
81. Fioramonti J, Christen MO, Dupre I, Bueno L. Involvement of a CCK-dependent capsaicin-sensitive afferent pathway in the inhibitory effect of pinaverium bromide on the colonic motor response to eating in rats. Fundam Clin Pharmacol 1997; 11: 231-236. [PMID: 9243254]
82. Levy C, Charbonnier A, Cachin M. [Pinaverium bromide and functional colonic disease (double-blind study]. Sem Hop Ther 1977; 53: 372-374. [PMID: 339352]
83. Fehér A, Wittmann T, Kiss J, Rosztóczy A, Varga I, Jánosi J. Therapeutic effect of pinaverium bromide in irritable bowel syndrome (IBS). A pilot study. Zeitschrift für Gastroenterologie 1993; 31: 71A
84. Wittmann T, Fehér A, Rosztóczy A, Jánosi J. [Effectiveness of pinaverium bromide therapy on colonic motility disorders in irritable bowel syndrome]. Orv Hetil 1999; 140: 469-473. [PMID: 10204402]
85. Awad RACV, Dibildox M, Santiago R, Camacho S. Reduction of post-prandial motility by pinaverium bromide a calcium channel blocker acting selectively on the gastrointestinal tract in patients with irritable bowel syndrome. Acta Gastroenterol Latinoam 1997; 27: 247-251
86. Bouchoucha M, Faye A, Devroede G, Arsac M. Effects of oral pinaverium bromide on colonic response to food in irritable bowel syndrome patients. Biomed Pharmacother 2000; 54: 381-387. [PMID: 10989977 DOI: 10.1016/S0753-3322(01)80005-6]
87. Jayanthi V, Malathi S, Ramathilakam B, Dinakaran N, Balasubramanian V, Mathew S. Role of pinaverium bromide in south Indian patients with irritable bowel syndrome. J Assoc Physicians India 1998; 46: 369-371. [PMID: 11273320]
88. López-Alvarenga JC, Sobrino-Cossío S, Remes-Troche JM, Chiu-Ugalde J, Vargas-Romero JA, Schmulson M. Polar vectors as a method for evaluating the effectiveness of irritable bowel syndrome treatments: an analysis with pinaverium bromide 100mg plus simethicone 300mg po bid. Rev Gastroenterol Mex 2013; 78: 21-27. [PMID: 23375823 DOI: 10.1016/ j.rgmx.2012.10.003]
89. Defrance P, Casini A. A comparison of the action of otilonium bromide and pinaverium bromide: study conducted under clinical control. Ital J Gastroenterol 1991; 23: 64-66. [PMID: 1756286]
90. Einarson A, Bailey B, Koren G. Pregnancy outcome of women exposed to pinaverium due to a dispensing error. Ann Pharmacother 1999; 33: 112-113. [PMID: 9972395]
91. Bueno L, Fioramonti J, Delvaux M, Frexinos J. Mediators and pharmacology of visceral sensitivity: from basic to clinical investigations. Gastroenterology 1997; 112: 1714-1743. [PMID: 9136853]
92. Subissi A, Brunori P, Bachi M. Effects of spasmolytics on K+-induced contraction of rat intestine in vivo. Eur J Pharmacol 1983; 96: 295-301. [PMID: 6144556]
93. Sasaki D, Kido A, Yoshida Y. Effect of antispasmodic drugs on colonic motility. Part I: Laboratory study of the dog. Int J Clin Pharmacol Ther Toxicol 1984; 22: 333-337. [PMID: 6147311]
94. Sasaki D, Kido A, Yoshida Y. Effect of antispasmodic drugs on the colonic motility. Part II: Clinical study in man. Int J Clin Pharmacol Ther Toxicol 1984; 22: 338-341. [PMID: 6147312]
95. Cargill G, Salin B, Lubin S, Kohler F, Coste T, Rautureau J. [Effect of phloroglucinol on rectosigmoid motility stimulated by a test meal. Study in patients with irritable bowel syndrome]. Presse Med 1992; 21: 19-23. [PMID: 1531259]
96. Louvel D, Delvaux M, Staumont G, Camman F, Fioramonti J, Bueno L, Frexinos J. Intracolonic injection of glycerol: a model for abdominal pain in irritable bowel syndrome? Gastroenterology 1996; 110: 351-361. [PMID: 8566580]
97. Jafri W, Yakoob J, Hussain S, Jafri N, Islam M. Phloroglucinol in irritable bowel syndrome. J Pak Med Assoc 2006; 56: 5-8. [PMID: 16454126]
98. Chassany O, Bonaz B, Bruley DES Varannes S, Bueno L, Cargill G, Coffin B, Ducrotté P, Grangé V. Acute exacerbation of pain in irritable bowel syndrome: efficacy of phloroglucinol/trimethylphloroglucinol. A randomized, double-blind, placebo-controlled study. Aliment Pharmacol Ther 2007; 25: 1115-1123. [PMID: 17439513 DOI: 10.1111/ j.1365-2036.2007.03296.x]
99. Cha BK, Choi CH, Kim BJ, Oh HC, Kim JW, Do JH, Kim JG, Chang SK. The Effect of Phloroglucinol in Diarrhea-Dominant Irritable Bowel Syndrome: Randomized, Double-Blind, Placebo-Controlled Trial. Gastroenterology 2011; 140: S-611-S-612
100. Lacroix I, Hurault-Delarue C, Kessler S, Guitard C, Vidal S, Albouy-Cossard C, Montastruc JL, Damase-Michel C. [First epidemiologic data about phloroglucinol exposure during first trimester of pregnancy]. Gynecol Obstet Fertil 2011; 39: 694-697. [PMID: 21855385 DOI: 10.1016/j.gyobfe.2011.07.013]
101. Huguenard JR. Low-threshold calcium currents in central nervous system neurons. Annu Rev Physiol 1996; 58: 329-348. [PMID: 8815798 DOI: 10.1146/annurev.ph.58.030196.001553]
102. Chemin J, Monteil A, Perez-Reyes E, Bourinet E, Nargeot J, Lory P. Specific contribution of human T-type calcium channel isotypes (alpha(1G), alpha(1H) and alpha(1I)) to neuronal excitability. J Physiol 2002; 540: 3-14. [PMID: 11927664]
103. Todorovic SM, Jevtovic-Todorovic V, Meyenburg A, Mennerick S, Perez-Reyes E, Romano C, Olney JW, Zorumski CF. Redox modulation of T-type calcium channels in rat peripheral nociceptors. Neuron 2001; 31: 75-85. [PMID: 11498052]
104. Zamponi GW, Lewis RJ, Todorovic SM, Arneric SP, Snutch TP. Role of voltage-gated calcium channels in ascending pain pathways. Brain Res Rev 2009; 60: 84-89. [PMID: 19162069 DOI: 10.1016/j.brainresrev.2008.12.021]
105. Choi S, Na HS, Kim J, Lee J, Lee S, Kim D, Park J, Chen CC, Campbell KP, Shin HS. Attenuated pain responses in mice lacking Ca(V)3.2 T-type channels. Genes Brain Behav 2007; 6: 425-431. [PMID: 16939637 DOI: 10.1111/j.1601-183X.2006.00268.x]
106. Todorovic SM, Meyenburg A, Jevtovic-Todorovic V. Mechanical and thermal antinociception in rats following systemic administration of mibefradil, a T-type calcium channel blocker. Brain Res 2002; 951: 336-340. [PMID: 12270514]
107. Flatters SJ, Bennett GJ. Ethosuximide reverses paclitaxel-and vincristine-induced painful peripheral neuropathy. Pain 2004; 109: 150-161. [PMID: 15082137 DOI: 10.1016/j.pain.2004.01.029]
108. Marger F, Gelot A, Alloui A, Matricon J, Ferrer JF, Barrère C, Pizzoccaro A, Muller E, Nargeot J, Snutch TP, Eschalier A, Bourinet E, Ardid D. T-type calcium channels contribute to colonic hypersensitivity in a rat model of irritable bowel syndrome. Proc Natl Acad Sci USA 2011; 108: 11268-11273. [PMID: 21690417 DOI: 10.1073/pnas.1100869108]
109. Bourdu S, Dapoigny M, Chapuy E, Artigue F, Vasson MP, Dechelotte P, Bommelaer G, Eschalier A, Ardid D. Rectal instillation of butyrate provides a novel clinically relevant model of noninflammatory colonic hypersensitivity in rats. Gastroenterology 2005; 128: 1996-2008. [PMID: 15940632]
110. Francois A, Kerckhove N, Meleine M, Alloui A, Barrere C, Gelot A, Uebele VN, Renger JJ, Eschalier A, Ardid D, Bourinet E. State-dependent properties of a new T-type calcium channel blocker enhance Ca(V)3.2 selectivity and support analgesic effects. Pain 2013; 154: 283-293. [PMID: 23257507 DOI: 10.1016/j.pain.2012.10.023]